Related Experiment Video
Updated: May 22, 2026

Pre-Chiasmatic, Single Injection of Autologous Blood to Induce Experimental Subarachnoid Hemorrhage in a Rat Model
Published on: June 18, 2021
Intravenous fluid administration may improve post-operative course of patients with chronic subdural hematoma: a
Miroslaw Janowski1, Przemyslaw Kunert
1Department of Neurosurgery, Medical University of Warsaw, Warsaw, Poland. mjanows1@jhmi.edu
Insights
Intravenous fluid administration (IFA) is a key factor in preventing chronic subdural hematoma (cSDH) recurrence. Administering at least 2000 ml over three days post-surgery can significantly lower recurrence rates.
Area of Science:
- Neurosurgery
- Clinical Medicine
- Patient Management
Background:
- Chronic subdural hematoma (cSDH) treatment carries a high risk of recurrence.
- Postoperative management strategies, particularly intravenous fluid administration (IFA), are understudied in cSDH.
- Limited research exists on the impact of IFA on cSDH outcomes.
Purpose of the Study:
- To investigate the impact of postoperative intravenous fluid administration (IFA) on chronic subdural hematoma (cSDH) recurrence.
- To identify patient management factors influencing hematoma recurrence and neurological outcomes.
Main Methods:
- Retrospective analysis of 45 cSDH patients treated with burr hole craniostomy and closed drainage.
- Independent variables included various patient management aspects, focusing on IFA.
- Dependent variables were hematoma recurrence rate (RHR) and Glasgow Outcome Scale (GOS) at discharge.
Main Results:
- Hematoma recurrence requiring re-operation occurred in 15% of patients.
- Univariate analysis showed IFA duration significantly impacted RHR (p=0.045) and GOS (p=0.023).
- Multivariate analysis identified IFA as the sole independent predictor of RHR. Patients receiving ≥2000 ml/day over 3 days had lower RHR (p=0.031).
Conclusions:
- Intravenous fluid administration (IFA) is a critical, independent factor influencing both cSDH recurrence and patient neurological outcomes.
- A recommended postoperative IFA regimen of at least 2000 ml per 3 days may reduce cSDH recurrence risk.
Background:
The treatment of chronic subdural hematoma (cSDH) is still charged of significant risk of hematoma recurrence. Patient-related predictors and the surgical procedures themselves have been addressed in many studies. In contrast, postoperative management has infrequently been subjected to detailed analysis. Moreover variable intravenous fluid administration (IFA) was not reported in literature till now in the context of cSDH treatment.
Methodology/Principal Findings:
A total of 45 patients with cSDH were operated in our department via two burr hole craniostomy within one calendar year. Downward drainage was routinely left in hematoma cavity for a one day. Independent variables selected for the analysis were related to various aspects of patient management, including IFA. Two dependent variables were chosen as measure of clinical course: the rate of hematoma recurrence (RHR) and neurological status at discharge from hospital expressed in points of Glasgow Outcome Scale (GOS). Univariate and multivariate regression analyses were performed. Hematoma recurrence with subsequent evacuation occurred in 7 (15%) patients. Univariate regression analysis revealed that length of IFA after surgery influenced both dependent variables: RHR (p = 0.045) and GOS (p = 0.023). Multivariate regression performed by backward elimination method confirmed that IFA is a sole independent factor influencing RHR. Post hoc dichotomous division of patients revealed that those receiving at least 2000 ml/day over 3 day period revealed lower RHR than the group with less intensive IFA. (p = 0.031).
Conclusions/Significance:
IFA has been found to be a sole factor influencing both: RHR and GOS. Based on those results we may recommend administration of at least 2000 ml per 3 days post-operatively to decrease the risk of hematoma recurrence.
Related Concept Videos
Aneurysm IV: Nursing Management
Venous Thrombosis III: Interprofessional Care
Hemorrhagic Stroke ll: Pathophysiology